Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takeshi Hashimoto

Showing results (311-320 of 319) with videos related to

Pageof 32
Sort By:
You have reached the last page of results.This site can display upto 319 results.
World Journal of Urology|November 4, 2023
Nephron-sparing ureteroscopic surgery vs. radical nephroureterectomy: comparable survival-outcomes in upper tract urothelial carcinomaTakuya Tsujino, Kazumasa Komura, Teruo Inamoto, et al.
Oncology|October 15, 2023
Predicting Objective Response of Pembrolizumab in Platinum-Refractory Urothelial Carcinoma Based on Neutrophil-Lymphocyte Ratio Fluctuation and Liver MetastasesKyosuke Nishio, Takuya Higashio, Kazumasa Komura, et al.
Targeted Oncology|May 28, 2024
C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial CarcinomaTaizo Uchimoto, Takuya Matsuda, Kazumasa Komura, et al.
Neuron|June 23, 2017
High-Speed and Scalable Whole-Brain Imaging in Rodents and PrimatesKaoru Seiriki, Atsushi Kasai, Takeshi Hashimoto, et al.
World Journal of Urology|February 24, 2025
Deciphering RCC immunotherapy outcomes: insights from a Japanese multi-institutional study on the CANLPH score's impactTatsuo Fukushima, Takuya Tsujino, Moritoshi Sakamoto, et al.
Scientific Reports|July 27, 2025
Eosinophils as a predictive marker of treatment-related adverse events in mRCC patients treated with first-line immune-checkpoint inhibitor combination therapyTatsushi Kawada, Satoshi Katayama, Takafumi Yanagisawa, et al.
Targeted Oncology|March 28, 2024
Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint InhibitorsTaizo Uchimoto, Shuya Tsuchida, Kazumasa Komura, et al.
International Journal of Clinical Oncology|January 31, 2025
Association of body mass index and tumor response in metastatic urothelial carcinoma treated with enfortumab vedotin: data from the ULTRA-Japan consortiumTaizo Uchimoto, Kengo Iwatsuki, Kazumasa Komura, et al.
International Journal of Clinical Oncology|October 29, 2024
Predicting time to castration resistance with androgen-receptor signaling inhibitors in hormone-sensitive prostate cancer: data from ULTRA-Japan ConsortiumTaizo Uchimoto, Kengo Iwatsuki, Kazumasa Komura, et al.
Pageof 32

Showing results (311-320 of 319) with videos related to

Sort By:
Pageof 32
You have reached the last page of results.This site can display upto 319 results.
World Journal of Urology|November 4, 2023
Nephron-sparing ureteroscopic surgery vs. radical nephroureterectomy: comparable survival-outcomes in upper tract urothelial carcinomaTakuya Tsujino, Kazumasa Komura, Teruo Inamoto, et al.
Oncology|October 15, 2023
Predicting Objective Response of Pembrolizumab in Platinum-Refractory Urothelial Carcinoma Based on Neutrophil-Lymphocyte Ratio Fluctuation and Liver MetastasesKyosuke Nishio, Takuya Higashio, Kazumasa Komura, et al.
Targeted Oncology|May 28, 2024
C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial CarcinomaTaizo Uchimoto, Takuya Matsuda, Kazumasa Komura, et al.
Neuron|June 23, 2017
High-Speed and Scalable Whole-Brain Imaging in Rodents and PrimatesKaoru Seiriki, Atsushi Kasai, Takeshi Hashimoto, et al.
World Journal of Urology|February 24, 2025
Deciphering RCC immunotherapy outcomes: insights from a Japanese multi-institutional study on the CANLPH score's impactTatsuo Fukushima, Takuya Tsujino, Moritoshi Sakamoto, et al.
Scientific Reports|July 27, 2025
Eosinophils as a predictive marker of treatment-related adverse events in mRCC patients treated with first-line immune-checkpoint inhibitor combination therapyTatsushi Kawada, Satoshi Katayama, Takafumi Yanagisawa, et al.
Targeted Oncology|March 28, 2024
Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint InhibitorsTaizo Uchimoto, Shuya Tsuchida, Kazumasa Komura, et al.
International Journal of Clinical Oncology|January 31, 2025
Association of body mass index and tumor response in metastatic urothelial carcinoma treated with enfortumab vedotin: data from the ULTRA-Japan consortiumTaizo Uchimoto, Kengo Iwatsuki, Kazumasa Komura, et al.
International Journal of Clinical Oncology|October 29, 2024
Predicting time to castration resistance with androgen-receptor signaling inhibitors in hormone-sensitive prostate cancer: data from ULTRA-Japan ConsortiumTaizo Uchimoto, Kengo Iwatsuki, Kazumasa Komura, et al.
Pageof 32